MX2024007066A - Uso de amivantamab para tratar el cancer colorrectal. - Google Patents

Uso de amivantamab para tratar el cancer colorrectal.

Info

Publication number
MX2024007066A
MX2024007066A MX2024007066A MX2024007066A MX2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A
Authority
MX
Mexico
Prior art keywords
colorectal cancer
amivantamab
antibody
treat colorectal
subject
Prior art date
Application number
MX2024007066A
Other languages
English (en)
Spanish (es)
Inventor
Roland Knoblauch
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2024007066A publication Critical patent/MX2024007066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024007066A 2021-12-09 2022-12-09 Uso de amivantamab para tratar el cancer colorrectal. MX2024007066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US202163290765P 2021-12-17 2021-12-17
PCT/IB2022/061991 WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Publications (1)

Publication Number Publication Date
MX2024007066A true MX2024007066A (es) 2024-06-21

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007066A MX2024007066A (es) 2021-12-09 2022-12-09 Uso de amivantamab para tratar el cancer colorrectal.

Country Status (9)

Country Link
US (2) US20230183360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444426A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500784A (cg-RX-API-DMAC7.html)
KR (1) KR20240112963A (cg-RX-API-DMAC7.html)
AU (1) AU2022407875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241933A1 (cg-RX-API-DMAC7.html)
IL (1) IL313410A (cg-RX-API-DMAC7.html)
MX (1) MX2024007066A (cg-RX-API-DMAC7.html)
WO (1) WO2023105479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
BR112022015140A2 (pt) * 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met

Also Published As

Publication number Publication date
KR20240112963A (ko) 2024-07-19
AU2022407875A1 (en) 2024-07-25
CA3241933A1 (en) 2023-06-15
EP4444426A1 (en) 2024-10-16
US20250257139A1 (en) 2025-08-14
IL313410A (en) 2024-08-01
WO2023105479A1 (en) 2023-06-15
JP2025500784A (ja) 2025-01-15
US20230183360A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CL2024001384A1 (es) Moleculas de anticuerpo y conjugados
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CL2022000495A1 (es) Formulaciones farmacéuticas y regímenes de dosificación para proteínas de unión multiespecíficas que se unen a her2, nkg2d y cd16 para el tratamiento del cáncer
DOP2021000013A (es) Proteínas terapéuticas de unión a dll4
BR112021012812A2 (pt) Csf1r inhibitors para uso e tratamento de câncer
CY1117241T1 (el) Αντισωματα anti-igf
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
FI3665198T3 (fi) EGFR:ää ja cMET:tä sitovia vasta-aineita
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
MX2019014316A (es) Un nuevo anticuerpo anti-c-met y uso del mismo.
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
CL2024002974A1 (es) Anticuerpos monoclonales y anticuerpo biespecifico contra c-met
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
PE20221830A1 (es) Anticuerpos especificos contra la claudina 18.2 tumoral
ZA202008095B (en) Humanized antibodies against psma
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
MX2023002104A (es) Composiciones y métodos para tratar cánceres positivos para egfr.
CY1125041T1 (el) Αντισωματα anti-il-22r
IL313410A (en) Use of amivantamab to treat colorectal cancer
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EA201491352A1 (ru) Способ лечения рака груди
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.